Alkermes Plc (OQ:ALKS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: Connaught HSE, 1 Burlington Road
DUBLIN 00000
Tel: N/A
Website: https://www.alkermes.com
IR: See website
<
Key People
Richard F. Pops
Chairman of the Board, Chief Executive Officer
Iain M. Brown
Chief Financial Officer, Senior Vice President
Blair C. Jackson
Chief Operating Officer, Executive Vice President
David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Craig C. Hopkinson
Executive Vice President, Research and Development and Chief Medical Officer
Michael J. Landine
Senior Vice President - Corporate Development, Chief Risk Officer
C.Todd Nichols
Senior Vice President, Chief Commercial Officer
   
Business Overview
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Financial Overview
For the fiscal year ended 31 December 2023, Alkermes Plc revenues increased 50% to $1.66B. Net income before extraordinary items totaled $519.2M vs. loss of $33.2M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment increase from $115.7M to $486.1M, LYBALVI segment increase of 100% to $191.9M, United States segment increase of 60% to $1.49B. Net Income reflects Interest Income increase from $7.6M to $30.9M (income).
Employees: 2,100 as of Feb 9, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $3,669M as of Dec 31, 2023
Annual revenue (TTM): $1,663M as of Dec 31, 2023
EBITDA (TTM): $495.05M as of Dec 31, 2023
Net annual income (TTM): $519.16M as of Dec 31, 2023
Free cash flow (TTM): $353.31M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 169,184,183 as of Mar 18, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.